Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Immutep ( (IMMP) ) just unveiled an announcement.
On September 22, 2025, Immutep announced a research collaboration with the George Washington University Cancer Center to initiate a Phase II trial evaluating its immunotherapy drug, eftilagimod alfa (efti), in early-stage HR+/HER2-negative breast cancer patients. The trial will explore efti as a monotherapy and in combination with chemotherapy, aiming to enhance the anti-cancer immune response and improve pathologic complete response rates. This collaboration marks a strategic expansion of Immutep’s clinical pipeline, potentially strengthening its position in the immunotherapy market and addressing high unmet medical needs.
The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.
Spark’s Take on IMMP Stock
According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.
Immutep’s overall stock score reflects the challenges and potential of a biotech firm in its developmental stage. Strong financial stability from a robust balance sheet is offset by negative profitability and cash flow. Technical analysis provides some optimism with balanced momentum signals, but valuation remains a concern due to ongoing losses. This score highlights the high-risk, high-reward nature of investing in early-stage biotech stocks.
To see Spark’s full report on IMMP stock, click here.
More about Immutep
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. It specializes in therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to stimulate or suppress the immune response. The company is dedicated to providing innovative treatment options and maximizing shareholder value.
Average Trading Volume: 78,588
Technical Sentiment Signal: Strong Sell
Current Market Cap: $242M
For detailed information about IMMP stock, go to TipRanks’ Stock Analysis page.